Now Gilead trading is paused for pending news. The only way this is good for Cytodyn is if it’s to announce a buyout of CYDY at $100/share. (This is not happening, by the way, though I’d enjoy the money if I was wrong) But otherwise what it probably means is they finally have a shred of positivity from trials and before you know it the fda will be tripping over themselves to throw approval at them. I still believe it’s going to be Leronlimab that makes the real difference but it feels like an insurmountable hill at times. Anything that works at all is welcome in my book, but it’s frustrating to be still in the shadows and this will probably shove us a little deeper for a bit.